mozenavir

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = (4R,5S,6S,7R)-1,3-bis[(3-aminophenyl)methyl]-4,7-dibenzyl-5,6-dihydroxy-1,3-diazepan-2-one

| image = Mozenavir.svg

| tradename = Mozenavir

| legal_US = Investigational New Drug

| legal_status =

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 174391-92-5

| PubChem = 154044

| UNII = 64OO8946ER

| ChemSpiderID = 135759

| C=33 | H=36 | N=4 | O=3

| SMILES = C1=CC=C(C=C1)C[C@@H]2[C@@H]([C@H]([C@H](N(C(=O)N2CC3=CC(=CC=C3)N)CC4=CC(=CC=C4)N)CC5=CC=CC=C5)O)O

| StdInChI=1S/C33H36N4O3/c34-27-15-7-13-25(17-27)21-36-29(19-23-9-3-1-4-10-23)31(38)32(39)30(20-24-11-5-2-6-12-24)37(33(36)40)22-26-14-8-16-28(35)18-26/h1-18,29-32,38-39H,19-22,34-35H2/t29-,30-,31+,32+/m1/s1

| StdInChIKey = KYRSNWPSSXSNEP-ZRTHHSRSSA-N

}}

Mozenavir (DMP-450) is an antiviral drug which was developed as a treatment for HIV/AIDS. It acts as an HIV protease inhibitor and binds to this target with high affinity,{{cite journal | vauthors = Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, Jadhav PK, De Lucca GV, Smyser TE, Klabe RM, Bacheler LT, Rayner MM, Seitz SP | display-authors = 6 | title = Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors | journal = Journal of Medicinal Chemistry | volume = 39 | issue = 11 | pages = 2156–69 | date = May 1996 | pmid = 8667359 | doi = 10.1021/jm960083n }}{{cite journal | vauthors = Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP | title = The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues | journal = Bioorganic & Medicinal Chemistry Letters | volume = 8 | issue = 7 | pages = 823–8 | date = April 1998 | pmid = 9871548 | doi = 10.1016/s0960-894x(98)00119-x }} however despite promising results in early testing,{{cite journal | vauthors = De Clercq E | title = Highlights in the development of new antiviral agents | journal = Mini Reviews in Medicinal Chemistry | volume = 2 | issue = 2 | pages = 163–75 | date = April 2002 | pmid = 12370077 | doi = 10.2174/1389557024605474 }}{{cite journal | vauthors = Hensen C, Hermann JC, Nam K, Ma S, Gao J, Höltje HD | title = A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors | journal = Journal of Medicinal Chemistry | volume = 47 | issue = 27 | pages = 6673–80 | date = December 2004 | pmid = 15615516 | doi = 10.1021/jm0497343 }} mozenavir was unsuccessful in human clinical trials. Studies continue into related derivatives.{{cite journal | vauthors = Li P, Wang S, Wang H, Yan H | title = 2-Symmetric HIV-1 Protease Inhibitors and Docking Study | journal = Biological & Pharmaceutical Bulletin | volume = 42 | issue = 2 | pages = 261–267 | date = 2019 | pmid = 30713256 | doi = 10.1248/bpb.b18-00705 | doi-access = free }}